The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N07 | Other nervous system drugs | |
| 3 | N07C | Antivertigo preparations | |
| 4 | N07CA | Antivertigo preparations | |
| 5 | N07CA02 | Cinnarizine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 90 mg |
| Active Ingredient | Description | |
|---|---|---|
| Cinnarizine |
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CINNARON Hard capsule | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| CINNARON Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| STUGERON Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
